



Hiran C Fernando FRCS, FRCSEd, FACS

Education: Medical School; Royal Free Hospital, University of London (1986)

Training:

- **UK-** various hospitals including Royal Brompton, Bristol Royal Infirmary (1987-91)
- **US; Gen Surgery;** Harbor UCLA/UC Irvine. **CT Surg;** UC Davis. **MIS Thor;** University Pittsburgh



Employment:

- Assistant Professor; University Pittsburgh (1998-2004)
- Associate Professor; Boston University (2004-2013)
- Professor (2013) & Chief Thoracic Surgery (2012); Boston University
- Professor & Co-Director Thoracic Oncology; Inova Fairfax Med Campus, Virginia Commonwealth University (2017-present)

Societies:

- | | |
|---|------|
| • European Society of Thoracic Surgeons | 2018 |
| • American Surgical Association | 2016 |
| • British Oesophageal Group | 2014 |
| • American Association for Thoracic Surgery | 2008 |
| • International Society for Minimally Invasive Cardiothoracic Surgery | 2005 |
| • International Society for Diseases of the Esophagus | 2004 |
| • General Thoracic Club | 2003 |
| • Society of Thoracic Surgeons | 2003 |
| • Society of American Gastrointestinal Endoscopic Surgeons | 1999 |
| • Royal College Surgeons England | 1991 |
| • Royal College Surgeons Edinburgh | 1990 |

Overview:

Dr Fernando's clinical interests have been in minimally invasive approaches for lung, esophageal and mediastinal disease. This includes VATS, robotic, endoscopic as well as percutaneous approaches for thoracic diseases. He has an interest in clinical trials, and in particular evaluating therapeutic approaches for high-risk operable and medically inoperable patients with lung cancer. He has been the Principal Investigator or Co-principal Investigator for several multi-institutional trials evaluating sublobar resection, radio-frequency ablation and SBRT for lung cancer. He has mentored several residents and students, and has over 140 peer-reviewed publications in addition to authoring several book chapters and abstracts. He has participated as a member of several guidelines committees for the Society of Thoracic Surgeons. Most recently he co-chaired an evidence-based guideline committee for the International Society of Minimally Invasive Cardiothoracic Surgery that evaluated the optimal approach to performing lobectomy for non-small cell lung cancer.